ERA
0.003
50%
HLX
0.001
-50%
4DX
0.77
35.1%
XGLR
0.004
-42.9%
8CO
0.035
34.6%
PRX
0.002
-33.3%
AUK
0.004
33.3%
OEL
0.004
-20%
FRX
0.008
33.3%
IFG
0.03
-18.9%
S2R
0.125
33%
PKD
0.028
-17.6%
ILT
0.285
32.6%
BRU
0.02
-16.7%
JAL
0.12
30.4%
ETM
0.07
-16.7%
AGD
0.051
27.5%
OSX
0.01
-16.7%
FBR
0.005
25%
TAR
0.01
-16.7%
VRC
0.005
25%
DEL
0.132
-14.8%
POD
0.047
23.7%
PIM
0.094
-14.5%
RUL
4.63
22.8%
ALM
0.006
-14.3%
AHK
0.42
21.7%
AVE
0.006
-14.3%
ATV
0.028
21.7%
BNL
0.006
-14.3%
AHN
0.006
20%
ENT
0.006
-14.3%
ARV
0.006
20%
ENV
0.006
-14.3%
MGU
0.012
20%
OMG
0.012
-14.3%
RLG
0.006
20%
SPX
0.006
-14.3%
RRR
0.096
20%
VHL
0.025
-13.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NEU Phase 2 trial shows significant improvements

Neuren Pharmaceuticals (ASX:NEU) announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome. Significant improvement was observed by both clinicians and caregivers from treatment | ASX announcement: https://www.neurenpharma.com/pdf/f9ca13b8-b75f-4ff5-a5b7-1dcb75d547d6/P2-trial-shows-significant-improvements-in-PhelanMcDermid.pdf #shorts